What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s has been quite complex and has evolved rapidly. Here's a breakdown of what happened and who is still operating legally:

What Happened with the FDA and Compounded GLP-1s?

The popularity and high demand for GLP-1 receptor agonists like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) led to widespread shortages and high prices. This created a fertile ground for compounding pharmacies to offer "generic" or "alternative" versions.

The FDA's primary concerns and actions have centered on:

1. Safety and Efficacy: The FDA does not review compounded drugs for safety, effectiveness, or quality. They found instances where compounded versions contained:

   • Different active ingredients: Many compounded "semaglutide" products actually contained semaglutide sodium or semaglutide acetate, which are different salt forms from the active ingredient in approved products (semaglutide base). These salt forms have not been proven safe or effective for human use and carry unknown risks.
   • Impure or sub-potent ingredients: Some compounded drugs were found to have active pharmaceutical ingredients (APIs) from unverified sources, lacking proper quality control, or not containing the stated amount of medication.
   • Sterility issues: Compounded injectables, if not prepared in sterile environments, pose a risk of serious infections.
   • Misleading advertising: Many compounding pharmacies and clinics were marketing these products as "generic" or "similar to" the brand-name drugs, which is misleading as they are not FDA-approved equivalents.

2. Violation of Compounding Rules: Compounding pharmacies are generally allowed to create custom medications for individual patients with specific needs (e.g., allergies to fillers, need for a different dosage form) when an FDA-approved drug is not available or suitable. They are not supposed to make copies of FDA-approved drugs in bulk, especially if the approved drug is readily available.

   • The "Shortage List" Nuance: When an FDA-approved drug is officially on the FDA's drug shortage list, compounding pharmacies can legally compound a version using the exact same active ingredient to meet patient needs. However, this rule was often misapplied or abused.
     • Semaglutide: While certain doses of Ozempic/Wegovy were on the shortage list at times, the FDA specifically warned against compounding semaglutide salt forms (sodium, acetate) because they are not the same as the FDA-approved semaglutide base. Currently, semaglutide (the base) is generally not on the shortage list, making compounding it problematic.
     • Tirzepatide: Mounjaro and Zepbound (tirzepatide) are currently on the FDA's drug shortage list, which means legitimate compounding of tirzepatide (the base) is permissible under very strict conditions (see below).

3. Warning Letters and Enforcement: The FDA has issued numerous warning letters to compounding pharmacies, telemedicine companies, and clinics for illegally marketing and distributing unapproved or misbranded GLP-1 products. They've also worked with state boards of pharmacy to take action.

Who is Still Operating Legally?

Operating legally in the GLP-1 space means adhering strictly to FDA regulations.

1. FDA-Approved Brand Name Medications: These are the gold standard and the only GLP-1s that are fully FDA-approved, rigorously tested, and subject to strict manufacturing quality control.

   • Eli Lilly: Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for weight loss).
   • Novo Nordisk: Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight loss).
   • Why they're legal: They have undergone extensive clinical trials, are proven safe and effective, and are manufactured to the highest standards.

2. Legitimate Compounding Pharmacies (Under Strict Conditions): While the FDA has cracked down on illegal compounding, compounding itself is not inherently illegal. It is legal only when specific, stringent conditions are met:

   • Drug Shortage: The exact FDA-approved drug must be on the FDA's official drug shortage list.
     • Currently: Tirzepatide (the active ingredient in Mounjaro and Zepbound) is currently on the FDA's drug shortage list. This means a legitimate compounding pharmacy could legally compound tirzepatide.
     • Semaglutide: Semaglutide (the base, found in Ozempic and Wegovy) is generally not on the shortage list for the formulations used for weight loss, making compounding it significantly riskier from a legal standpoint.
   • Using Approved Active Pharmaceutical Ingredients (APIs): The pharmacy must use APIs from an FDA-registered manufacturer, ensuring purity and quality.
   • No "Salt Forms" for Semaglutide: Legitimate compounding pharmacies will not use semaglutide sodium or semaglutide acetate, as these are not the approved active ingredient.
   • Individualized Prescription: The compounded drug must be prescribed by a licensed physician for an individual patient, based on a specific medical need (e.g., allergy to a filler in the commercial product, need for a different dosage form). It's not for bulk manufacturing or general sales.
   • Licensed Pharmacy: The pharmacy must be licensed by the state board of pharmacy and adhere to compounding standards (e.g., USP <797> for sterile preparations).
   • No False Advertising: They cannot market their compounded products as "generic" or "FDA-approved" versions of the brand names.

   How to identify a potentially legitimate compounding source (still exercise extreme caution):

   • They are transparent about their sourcing of APIs.
   • They clearly state they are compounding tirzepatide (if it's on the shortage list) and not semaglutide salts.
   • They require a valid, individualized prescription from a licensed healthcare provider after a thorough medical evaluation.
   • They do not make unsubstantiated claims about their product being identical to the brand name or cheaper than the brand name.
   • They are typically a 503A pharmacy (traditional compounding pharmacy for individual prescriptions) or a 503B outsourcing facility (which produces larger batches but is held to higher manufacturing standards and must register with the FDA).

In summary, if you are seeking GLP-1 medications, the safest and most reliable options are the FDA-approved brand-name drugs: Ozempic, Wegovy, Mounjaro, and Zepbound. If considering a compounded option, be extremely cautious, verify the specific active ingredient (tirzepatide base, NOT semaglutide salts), and ensure it's from a highly reputable, transparent compounding pharmacy under a physician's direct care. Always consult with your doctor to determine the most appropriate and safe treatment plan for you.